Spots Global Cancer Trial Database for Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort
Official Title: Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies
Study ID: NCT03900442
Interventions
Study Description
Brief Summary: This is an open-label, non-randomized study to evaluate the PD, PK, and safety of 500 to 2000 mg/m2 PTX-100 in patients with advanced malignancies. PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles unless toxicity is observed. Dose escalation is complete and the expansion is open and actively recruiting PTCL patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
Epworth Healthcare, Melbourne, Victoria, Australia
Contact Details
Name: Terrence Chew, MD
Affiliation: Prescient Therapeutics, Ltd.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
